CN1580774A - 乳腺癌的Her-2免疫组织化学诊断试剂盒 - Google Patents
乳腺癌的Her-2免疫组织化学诊断试剂盒 Download PDFInfo
- Publication number
- CN1580774A CN1580774A CN 200410020546 CN200410020546A CN1580774A CN 1580774 A CN1580774 A CN 1580774A CN 200410020546 CN200410020546 CN 200410020546 CN 200410020546 A CN200410020546 A CN 200410020546A CN 1580774 A CN1580774 A CN 1580774A
- Authority
- CN
- China
- Prior art keywords
- antibody
- breast cancer
- reagent
- pamam
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 43
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title claims abstract description 43
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 42
- 230000002055 immunohistochemical effect Effects 0.000 title claims abstract description 20
- 238000009007 Diagnostic Kit Methods 0.000 title abstract 2
- 229920000962 poly(amidoamine) Polymers 0.000 claims abstract description 46
- 238000003745 diagnosis Methods 0.000 claims abstract description 34
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 239000002981 blocking agent Substances 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 13
- 241001494479 Pecora Species 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 22
- 239000012916 chromogenic reagent Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000013016 damping Methods 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 238000011161 development Methods 0.000 claims description 14
- 238000004043 dyeing Methods 0.000 claims description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 230000003647 oxidation Effects 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- SENLDUJVTGGYIH-UHFFFAOYSA-N n-(2-aminoethyl)-3-[[3-(2-aminoethylamino)-3-oxopropyl]-[2-[bis[3-(2-aminoethylamino)-3-oxopropyl]amino]ethyl]amino]propanamide Chemical compound NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN SENLDUJVTGGYIH-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 238000010186 staining Methods 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 claims description 3
- 244000227633 Ocotea pretiosa Species 0.000 claims description 3
- 235000004263 Ocotea pretiosa Nutrition 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000012758 nuclear staining Methods 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 238000010129 solution processing Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 8
- 229940022353 herceptin Drugs 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- -1 amide compound Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- GTDOPRQDTRLYAL-UHFFFAOYSA-N hydrogen peroxide;methanol Chemical compound OC.OO GTDOPRQDTRLYAL-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410020546XA CN1296711C (zh) | 2004-05-14 | 2004-05-14 | 乳腺癌的Her-2免疫组织化学诊断试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410020546XA CN1296711C (zh) | 2004-05-14 | 2004-05-14 | 乳腺癌的Her-2免疫组织化学诊断试剂盒 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510119865 Division CN1854711A (zh) | 2004-05-14 | 2004-05-14 | 乳腺癌的Her-2免疫组织化学诊断试剂盒检测对象的处理方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1580774A true CN1580774A (zh) | 2005-02-16 |
CN1296711C CN1296711C (zh) | 2007-01-24 |
Family
ID=34581872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410020546XA Expired - Fee Related CN1296711C (zh) | 2004-05-14 | 2004-05-14 | 乳腺癌的Her-2免疫组织化学诊断试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1296711C (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1928563B (zh) * | 2005-09-09 | 2010-04-28 | 上海张江生物技术有限公司 | 乳腺癌的免疫组化诊断试剂盒和测试片 |
CN102103142A (zh) * | 2010-12-30 | 2011-06-22 | 辽宁迈迪生物科技有限公司 | Tafi含量的体外检测方法 |
CN102183635A (zh) * | 2010-12-30 | 2011-09-14 | 辽宁迈迪生物科技有限公司 | Tafi含量的体外检测试剂盒 |
CN103308680A (zh) * | 2013-06-05 | 2013-09-18 | 南昌大学 | 志贺氏菌在复杂基质中磁富集分离方法 |
CN103675288A (zh) * | 2013-12-26 | 2014-03-26 | 泸州医学院 | 一种血小板标记物及其制备方法 |
CN105403704A (zh) * | 2015-12-31 | 2016-03-16 | 苏州市博纳泰科生物技术有限公司 | Her-2的荧光免疫层析检测方法及试剂盒 |
CN105566499A (zh) * | 2016-01-06 | 2016-05-11 | 广州深达生物制品技术有限公司 | 一种多聚体酶-抗体及其制备方法 |
CN106855575A (zh) * | 2016-12-30 | 2017-06-16 | 广州华弘生物科技有限公司 | 一种乳腺癌三联快速检测试剂盒 |
CN106932583A (zh) * | 2015-12-29 | 2017-07-07 | 北京大成生物工程有限公司 | 人表皮生长因子受体Her-2/neu定量检测试剂盒及其制备方法与应用 |
CN109682967A (zh) * | 2018-12-17 | 2019-04-26 | 暨南大学 | Pamam在制备用于免疫检测的试剂中的应用 |
CN109856383A (zh) * | 2019-03-05 | 2019-06-07 | 湖北泰康医疗设备有限公司 | 一种用于宫颈癌辅助诊断的免疫化学染色试剂盒 |
CN110632324A (zh) * | 2019-09-25 | 2019-12-31 | 百盛(广州)生物制品有限公司 | 用于二抗检测系统的聚酰胺胺结构多聚物及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101256190B (zh) * | 2008-03-27 | 2012-09-19 | 北京美康生物技术研究中心 | Ca15-3、cea、ca19-9、ca12-5、sf乳腺癌胶体金五联检诊断试剂盒 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US6585956B2 (en) * | 1997-07-07 | 2003-07-01 | The Dow Chemical Company | Dendritic-platinate drug delivery system |
CN1118568C (zh) * | 1998-07-22 | 2003-08-20 | 中国科学技术大学 | 抗P185neu/c-erbB-2单克隆抗体杂交瘤其制备方法及肿瘤检测用途 |
AUPP584398A0 (en) * | 1998-09-14 | 1998-10-08 | Starpharma Limited | Inhibition of toxic materials or substances |
AUPP584298A0 (en) * | 1998-09-14 | 1998-10-08 | Starpharma Limited | Antimicrobial and antiparasitic agents |
KR100426452B1 (ko) * | 2001-01-02 | 2004-04-13 | 김진우 | 인간 원암 유전자로 형질전환된 포유동물 및 이 유전자를이용한 유방암, 신장암, 난소암 또는 위암 진단용 키트 |
US20040072263A1 (en) * | 2002-04-19 | 2004-04-15 | Baylor College Of Medicine | Quantitative measurement of proteins using genetically-engineered glucose oxidase fusion molecules |
-
2004
- 2004-05-14 CN CNB200410020546XA patent/CN1296711C/zh not_active Expired - Fee Related
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1928563B (zh) * | 2005-09-09 | 2010-04-28 | 上海张江生物技术有限公司 | 乳腺癌的免疫组化诊断试剂盒和测试片 |
CN102103142A (zh) * | 2010-12-30 | 2011-06-22 | 辽宁迈迪生物科技有限公司 | Tafi含量的体外检测方法 |
CN102183635A (zh) * | 2010-12-30 | 2011-09-14 | 辽宁迈迪生物科技有限公司 | Tafi含量的体外检测试剂盒 |
CN103308680B (zh) * | 2013-06-05 | 2014-12-31 | 南昌大学 | 志贺氏菌在复杂基质中磁富集分离方法 |
CN103308680A (zh) * | 2013-06-05 | 2013-09-18 | 南昌大学 | 志贺氏菌在复杂基质中磁富集分离方法 |
CN103675288B (zh) * | 2013-12-26 | 2015-10-28 | 泸州医学院 | 一种血小板标记物及其制备方法 |
CN103675288A (zh) * | 2013-12-26 | 2014-03-26 | 泸州医学院 | 一种血小板标记物及其制备方法 |
CN106932583A (zh) * | 2015-12-29 | 2017-07-07 | 北京大成生物工程有限公司 | 人表皮生长因子受体Her-2/neu定量检测试剂盒及其制备方法与应用 |
CN105403704A (zh) * | 2015-12-31 | 2016-03-16 | 苏州市博纳泰科生物技术有限公司 | Her-2的荧光免疫层析检测方法及试剂盒 |
CN105566499A (zh) * | 2016-01-06 | 2016-05-11 | 广州深达生物制品技术有限公司 | 一种多聚体酶-抗体及其制备方法 |
CN105566499B (zh) * | 2016-01-06 | 2017-06-16 | 广州深达生物制品技术有限公司 | 一种多聚体酶‑抗体及其制备方法 |
CN106855575A (zh) * | 2016-12-30 | 2017-06-16 | 广州华弘生物科技有限公司 | 一种乳腺癌三联快速检测试剂盒 |
CN109682967A (zh) * | 2018-12-17 | 2019-04-26 | 暨南大学 | Pamam在制备用于免疫检测的试剂中的应用 |
CN109856383A (zh) * | 2019-03-05 | 2019-06-07 | 湖北泰康医疗设备有限公司 | 一种用于宫颈癌辅助诊断的免疫化学染色试剂盒 |
CN110632324A (zh) * | 2019-09-25 | 2019-12-31 | 百盛(广州)生物制品有限公司 | 用于二抗检测系统的聚酰胺胺结构多聚物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1296711C (zh) | 2007-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1296711C (zh) | 乳腺癌的Her-2免疫组织化学诊断试剂盒 | |
Ciocca et al. | Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells | |
CN1928563B (zh) | 乳腺癌的免疫组化诊断试剂盒和测试片 | |
CN106086177A (zh) | 癌的检测方法 | |
JPH0372894A (ja) | 悪性腫瘍細胞の検出 | |
CN1533440A (zh) | P2y嘌呤受体的表达在鉴定肿瘤前期和肿瘤状态中的应用 | |
KR850001770B1 (ko) | 인체 암 항원에 대한 특이항체의 제조방법 | |
CN108414756A (zh) | 一种同时检测尿液中四个膀胱癌标志物的蛋白芯片的制备方法 | |
CN1766634A (zh) | 一种检测乳腺球蛋白的方法及其试剂盒 | |
CN1718588A (zh) | 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断方法、诊断试剂盒及其应用 | |
CN1854711A (zh) | 乳腺癌的Her-2免疫组织化学诊断试剂盒检测对象的处理方法 | |
CN109709328B (zh) | 一种卵巢癌的诊断标志物及其应用 | |
CN102803968A (zh) | 食道癌标志物 | |
CN1296567A (zh) | 用于检测动物怀孕的方法和装置 | |
Sheikh et al. | Malignant glial neoplasms: definition of a humoral host response to tumor-associated antigen (s) | |
WO1990002333A1 (en) | Monoclonal antibody specific to a novel mucin-like glycoproteine antigen on human carcinoma cells | |
CN114164181A (zh) | 一种产生牛妊娠相关糖蛋白pag8单克隆抗体的杂交瘤细胞株及其应用 | |
CN108003239A (zh) | 一种全人源抗egfr单链抗体及其应用 | |
CN110835650B (zh) | 乳腺癌转移和预后诊断的生物标志物 | |
CN108414755A (zh) | 一种同时检测尿液中四个膀胱癌标志物的蛋白芯片 | |
CN116515786B (zh) | 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用 | |
US5312751A (en) | Hybridoma producing a monoclonal antibody specific for an antigen of the stratum corneum of human epidermis | |
AU571287B2 (en) | Cell line and monoclonal antibody | |
JPH1175839A (ja) | モノクローナル抗体、細胞株及びn1,n12−ジアセチルスペルミンの測定法 | |
CN118067996B (zh) | 一种PDK1 Nedd8修饰的结直肠癌标志物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LI WENXIN Free format text: FORMER OWNER: MAIDI BIOLOGICAL MEDICAL TECHNOLOGY CO., LTD., SHENYANG Effective date: 20101026 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20101026 Address after: Hunnan New Century Road 110179 Shenyang city of Liaoning Province, No. 29 overseas students G of garden Patentee after: Li Wenxin Address before: Hunnan New Century Road 110179 Shenyang city of Liaoning Province, No. 29 overseas students G of garden Patentee before: Maidi Biological Medical Technology Co., Ltd., Shenyang |
|
ASS | Succession or assignment of patent right |
Owner name: LIAONING MAIDI BIO-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LI WENXIN Effective date: 20101223 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110179 TOWER G, OVERSEAS STUDENTS PARK, NO.29, SHIJI ROAD, HUNNAN NEW DISTRICT, SHENYANG CITY, LIAONING PROVINCE TO: 117004 BUILDING 166, XIANGHUAI ROAD, ECONOMIC DEVELOPMENT ZONE, BENXI CITY, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101223 Address after: 117004 Liaoning Province, Benxi City Economic Development Zone Cladrastis road 166 Patentee after: Liaoning Maidi Biologic Technology Co., Ltd. Address before: Hunnan New Century Road 110179 Shenyang city of Liaoning Province, No. 29 overseas students G of garden Patentee before: Li Wenxin |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 117004 Liaoning Province, Benxi City Economic Development Zone Cladrastis road 166 Patentee after: Liaoning Maidi biological Polytron Technologies Inc Address before: 117004 Liaoning Province, Benxi City Economic Development Zone Cladrastis road 166 Patentee before: Liaoning Maidi Biologic Technology Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hel-2 immunohistochemical diagnostic kit for breast cancer Effective date of registration: 20190505 Granted publication date: 20070124 Pledgee: Chaoyang Bank Co., Ltd. Benxi Branch Pledgor: Liaoning Maidi biological Polytron Technologies Inc Registration number: 2019210000013 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200513 Granted publication date: 20070124 Pledgee: Chaoyang Bank Co., Ltd. Benxi Branch Pledgor: LIAONING MEDI BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: 2019210000013 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070124 Termination date: 20200514 |
|
CF01 | Termination of patent right due to non-payment of annual fee |